Market Intelligence for Decoy Receptor Therapeutics, Cardiovascular Modulators, and Antiviral Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ACE2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ACE2 ECD-Fc / Full-Length Protein – High purity (>95%), Endotoxin <1EU/ug. HEK293 expressed (native glycosylation). Sequence verified. | View ACE2 Products |
| Gene Delivery | ACE2 Promise-ORF / Lentivirus – Full-length ORF for stable cell lines and viral entry assays. | View ACE2 Products |
| Benchmark Ab | Anti-ACE2 (clinical benchmark sequence / research grade) – Recombinant positive control for binding/blocking assays. | View ACE2 Products |
| Validator | ACE2 siRNA Set – For knockdown verification and specificity controls. | View ACE2 Products |
| Related Target A | TMPRSS2 – Viral entry co-receptor and spike-priming protease; essential for pseudovirus entry assays. | View TMPRSS2 Products |
| Related Target B | AGTR1 (AT1R) – Angiotensin II receptor type 1, critical node in the RAAS pathway; antagonistic to ACE2 function. | View AGTR1 Products |
| Related Target C | ACE – Homolog counter-regulatory enzyme in the RAAS axis; critical for selectivity counter-screening. | View ACE Products |
| Related Target D | ADAM17 – Sheddase that cleaves ACE2, regulating soluble ACE2 levels and receptor turnover. | View ADAM17 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Glycosylation-Dependent Binding / Native Conformation | HEK293 expressed (native glycosylation); sequence verified; preserves accurate receptor-ligand kinetics. |
| Transmembrane Conformation Preservation | Premade lentivirus particles for rapid stable cell line generation; full-length surface expression detected by flow cytometry. |
| Lack of Reliable Controls / Positive Controls | Anti-ACE2 recombinant benchmark antibody (sequence verified) included. |
| Off-Target False Positives / Homolog Selectivity | Validated ACE2 siRNA set for knockdown checks; human ACE ortholog (>95% purity, mass spec verified) available for counter-screening. |
| Enzymatic Activity Preservation (Cardiovascular drug screening) | Catalytic domain (H374, H378, E402) sequence verified; active site accessibility confirmed for Angiotensin II cleavage assays. |
| Cross-species Spike Binding (Cyno/Mouse models) | Human/Mouse/Cyno ACE2 ortholog proteins with >95% purity, HEK293 expressed for native glycosylation patterns. |
| Resistance Mutant Validation (Viral escape) | Key mutation panel available (K26R, T27A) for binding escape analysis; sequence verified. |
| Shedding Stability (ADAM17 resistance) | ECD constructs engineered with sheddase-resistant linkers; endotoxin controlled (<1EU/ug). |
Global Clinical Landscape & Future Outlook
The ACE2 therapeutic landscape has transitioned from emergency COVID-19 decoy strategies to chronic cardiovascular and fibrotic disease modulation. Initially thrust into the spotlight as the primary entry receptor for SARS-CoV-2, ACE2 is now undergoing a renaissance in pulmonary arterial hypertension (PAH), acute respiratory distress syndrome (ARDS), and heart failure via renin-angiotensin-aldosterone system (RAAS) modulation. Major players include Apeiron Biologics (APN01, Phase 2/3 for ARDS/PAH), Alteogen (ALT-100 long-acting sACE2-Fc), and academic groups exploring gene therapy. The next wave focuses on half-life-extended Fc fusions, tissue-specific delivery (e.g., AAV-ACE2 for heart failure), small molecule activators, and bispecific decoys targeting the ACE2-TMPRSS2 axis to prevent viral escape.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Soluble Recombinant Protein (sACE2 / Decoy) | Apeiron Biologics, GSK, Alteogen | COVID-19, ARDS, PAH | Enzymatic & binding assays (need high-purity ECD-Fc with native glycosylation) |
| Monoclonal Antibody (Entry Blocker) | Vir Biotechnology, AbbVie, academic pipelines | Viral neutralization | Blocking assay (need full-length cell-surface ACE2) |
| Gene Therapy (AAV / Lentivirus) | Preclinical academic & biotech | Heart failure, pulmonary hypertension | Expression validation (need ORF lentivirus for stable cell line construction) |
| Small Molecule Enhancers / Activators | University of Alberta, Bayer | Cardiovascular disease, hypertension | Catalytic activity assay (need enzymatically active, properly folded protein) |
| Bispecific Decoys | Vicore Pharma, DICE Therapeutics | ARDS, fibrosis | Heterodimer validation (need high-affinity ACE2 domain with stable formulation) |
Key Functional Domains & Mutations (UniProt Q9BYF1)
ACE2 comprises two main functional domains: a Peptidase M2 domain (zinc metallopeptidase responsible for Angiotensin II cleavage) and a Collectrin-like domain (involved in amino acid transport). Clinically relevant mutations include dbSNP:rs4646116 (VAR_023082) and dbSNP:rs183135788 (VAR_023083), which have been linked to altered enzyme activity or viral binding affinity. These variants are essential for studying resistance mechanisms and patient stratification.